Abstract: The invention relates to a method for producing, amongst other things, amino-acid and/or hydroxycarboxylic-acid metal chelates, a solvent-free mixture of at least one metal oxide, metal hydroxide, metal carbonate or oxalate, and the solid organic acid is subjected to intensive mechanical stress. According to the invention, this is done in that the reaction partners are introduced in particle form into a fluid stream of a fluid-bed countercurrent mill operating without grinding elements, wherein mechanical activation of at least one of the reaction partners is effected by collision processes within a reaction chamber formed in a region of the fluid stream, and a solid body reaction to form the metal chelate is triggered. The novel method operates very energy-efficiently and with a high specific yield. It leads to a product having compact particles in the small, single-digit micrometer range having a comparatively narrow particle sizc distribution and a large surface. The product is homogenous and very pure.

Abstract: The present invention concerns a pharmaceutically acceptable salt of a compound of the following formula (I): H2N—CH(R1)—CH2S—S—CH2—CH(R2—CONH—CH(R3)—COOR4 (I) and more particularly an acid addition salt thereof, and the compositions comprising the same, for use in the prevention or treatment of trigeminal nerve pain, in particular migraines or trigeminal neuralgia.

Abstract: Compositions comprising a mixture of at least one cyclodextrin, a carrier, and optionally one or more vitamins and/or nutrients to improve at least one health factor of a beehive is disclosed. Methods of improving beehive health and apparatuses including such compositions are also disclosed.

Abstract: Prodrugs of colchicine, de-acetyl colchicine, colcemid, and nocodazole are provided as therapies for the treatment of diseases ameliorated by the inhibition of microtubule polymerization.

Abstract: Provided are compounds and methods for treating neurodegenerative diseases and conditions, such as multiple sclerosis, using an estrogen receptor-? ligand (ER? ligand).

Abstract: The present invention relates to a tablet comprising one or more omega-3 fatty acid amino acid salts, a method for preparing a tablet according to the invention and the use of a tablet according to the invention as a food supplement or as a pharmaceutical product.

Abstract: A method of distinguishing between urothelial carcinoma and squamous cell carcinoma of head and neck and lung primaries is presented. A 19-gene signature was developed which differentiates between metastatic urothelial carcinoma and squamous cell carcinoma in a metastatic site when the primary site is either known or unknown.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.

Abstract: Compositions and methods for inducing weight loss, fat loss, maintaining weight or fat loss, suppressing appetite, reducing calorie intake, reducing weight gain, decreasing feed efficiency, increasing metabolic inefficiency, increasing energy expenditure, increasing thermogenesis and/or resetting metabolic set are disclosed. The compositions have a therapeutically effective amount of a ketogenic supplement, e.g., a ketone diesters, such as R,S 1,3-butanediol diacetoacetate. Compositions of one or more beta-hydroxybutyrate, beta-hydroxybutyrate salt, and medium chain triglycerides are also disclosed.

Abstract: The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative. In addition, modified-release formulations comprising at least one anti-methanogenic lovastatin analog or derivative are provided which release the anti-methanogenic lovastatin analog or derivative in the gastrointestinal tract.

Abstract: The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the hematopoietic system including the hematologic system in human and veterinary medicine.

Abstract: The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.

Abstract: The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same.

Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: A method is provided for treatment of symptoms of Ehlers-Danlos Syndromes comprising administration of a composition comprising rubeola virus, histamine and collagen.

Abstract: The present disclosure provides compositions and methods for the treatment of inflammation in urological pathologies.

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Abstract: Disclosed compositions comprise a therapeutic agent and a carrier selected, or processed to have, an acceptable composite flow index, a granular particle size of 18 mesh to 80 mesh, or both, such as processed granular wheat middlings. The composition may also comprise an oil and/or micro tracers. Suitable granular wheat middlings may have a size range of from 18 mesh to 80 mesh, such as 20 mesh to 80 mesh. The composition has improved flowability characteristics, compared to a composition where the carrier, such as processed wheat middlings, are powdered and/or flakey. Certain embodiments concern a composition comprising, consisting essentially of, or consisting of, nicarbazin, granular wheat middlings, soybean oil and micro tracers. The composition may be administered to an animal, for example, to treat or prevent coccidiosis. Also disclosed herein are methods for making and using the composition.